The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer

20260 citationsJournal Articlehybrid Open Access

Authors

Michael Cecchini · Yale University

S. W. Han · Seoul National University Hospital

Soohyeon Lee · University of Seoul

Keun-Wook Lee · Seoul National University Bundang Hospital

Scott Kopetz · The University of Texas MD Anderson Cancer Center

Jonathan D. Mizrahi · Ochsner Health System

Yong Sang Hong

Abstract

EZFB significantly improved survival outcomes compared with regorafenib in patients with mCRC as a third-line treatment, with a manageable safety profile. Further investigation is warranted, given the clinically meaningful improvements in progression-free survival and overall survival.

Topics & Keywords

Colorectal Cancer Treatments and Studies Advanced Breast Cancer Therapies Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-25-3727

Field-Weighted Citation Impact: 0.00